Works by Tibben, Matthijs

Results: 17

A phase 0 clinical trial of novel candidate extended-release formulations of capecitabine.

Published in:

2016

By:

Jacobs, Bart;
Meulenaar, Jelte;
Rosing, Hilde;
Pluim, Dick;
Tibben, Matthijs;
Vries, Niels;
Nuijen, Bastiaan;
Huitema, Alwin;
Beijnen, Jos;
Schellens, Jan;
Marchetti, Serena;
Jacobs, Bart A W;
Tibben, Matthijs M;
de Vries, Niels;
Huitema, Alwin D R;
Beijnen, Jos H;
Schellens, Jan H M

Publication type:

journal article

Phase I Study of Sorafenib Combined with Gemcitabine and Carboplatin in Patients with Advanced Solid Tumors.

Published in:

Oncology & Therapy, 2025, v. 13, n. 2, p. 465, doi. 10.1007/s40487-025-00340-8

By:

Voogd, Daphne W. M.;
Lucassen, Merel J. J.;
van der Noll, Ruud;
Zielhuis, Sybrand W. J.;
Boss, David;
Beijnen, Jos H.;
Rosing, Hilde;
Tibben, Matthijs;
Huitema, Alwin D. R.;
Schellens, Jan H. M.;
Steeghs, Neeltje

Publication type:

Article

Toxicological analysis of azide and cyanide for azide intoxications using gas chromatography.

Published in:

Basic & Clinical Pharmacology & Toxicology, 2021, v. 128, n. 3, p. 534, doi. 10.1111/bcpt.13523

By:

Bruin, Maaike A. C.;
Dekker, Douwe;
Venekamp, Nikkie;
Tibben, Matthijs;
Rosing, Hilde;
de Lange, Dylan W.;
Beijnen, Jos H.;
Huitema, Alwin D. R.

Publication type:

Article

Acute poisoning after oral intake of a toluene-containing paint thinner.

Published in:

2002

By:

Malingré, Mirte M.;
Hendrix, Emile A.;
Schellens, Jan M.;
Koks, Cees W.;
Tibben, Matthijs M.;
Challa, Eric E.;
Beijnen, Jos H.;
Schellens, Jan H M;
Koks, Cees H W

Publication type:

journal article

Is Higher Docetaxel Clearance in Prostate Cancer Patients Explained by Higher CYP3A? An In Vivo Phenotyping Study with Midazolam.

Published in:

Journal of Clinical Pharmacology, 2024, v. 64, n. 2, p. 155, doi. 10.1002/jcph.2362

By:

van der Heijden, Lisa T.;
Ribbers, Claire A.;
Vermunt, Marit A.C.;
Pluim, Dick;
Acda, Manon;
Tibben, Matthijs;
Rosing, Hilde;
Douma, Joeri A.J.;
Naipal, Kishan;
Bergman, Andre M.;
Beijnen, Jos H.;
Huitema, Alwin D.R.;
Opdam, Frans L.

Publication type:

Article

Determination of ruthenium originating from the investigational anti-cancer drug NAMI-A in human plasma ultrafiltrate, plasma, and urine by inductively coupled plasma mass spectrometry.

Published in:

Rapid Communications in Mass Spectrometry: RCM, 2007, v. 21, n. 9, p. 1521, doi. 10.1002/rcm.2985

By:

Brouwers, Elke E. M.;
Tibben, Matthijs M.;
Rosing, Hilde;
Schellens, Jan H. M.;
Beijnen, Jos H.

Publication type:

Article

Quantitative analysis of D-24851, a novel anticancer agent, in human plasma and urine by liquid chromatography coupled with tandem mass spectrometry.

Published in:

Rapid Communications in Mass Spectrometry: RCM, 2004, v. 18, n. 13, p. 1465, doi. 10.1002/rcm.1493

By:

Stokvis, Ellen;
Nan-Offeringa, Lianda G. A. H.;
Ouwehand, Mariët;
Tibben, Matthijs M.;
Rosing, Hilde;
Schnaars, Yvonne;
Grigat, Martina;
Romeis, Peter;
Schellens, Jan H. M.;
Beijnen, Jos H.

Publication type:

Article

A simple extemporaneous oral suspension of aprepitant yields sufficient pharmacokinetic exposure in children.

Published in:

Journal of Oncology Pharmacy Practice, 2023, v. 29, n. 4, p. 899, doi. 10.1177/10781552221089243

By:

Nijstad, A Laura;
de Vos-Kerkhof, Evelien;
Enters-Weijnen, Catherine F;
van de Wetering, Marianne D;
Tissing, Wim J E;
Hanff, Lidwien M;
Lange, Rogier;
Tibben, Matthijs M;
Rosing, Hilde;
Lalmohamed, Arief;
Zwaan, C Michel;
Huitema, Alwin D R

Publication type:

Article

Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin.

Published in:

Cancer Chemotherapy & Pharmacology, 2002, v. 49, n. 3, p. 201, doi. 10.1007/s002800100371

By:

Terwogt, Jetske M. Meerum;
Groenewegen, Gerard;
Pluim, Dick;
Maliepaard, Marc;
Tibben, Matthijs M.;
Huisman, Albert;
ten Bokkel Huinink, Wim W.;
Schot, Margaret;
Welbank, Helen;
Voest, Emile E.;
Beijnen, Jos H.;
Schellens, Jan H. M.

Publication type:

Article

Validation of techniques for the prediction of carboplatin exposure: Application of Bayesian methods<sup>*</sup>.

Published in:

Clinical Pharmacology & Therapeutics, 2000, v. 67, n. 6, p. 621, doi. 10.1067/mcp.2000.106827

By:

Huitema, Alwin D. R.;
Mathôt, Ron A. A.;
Tibben, Matthijs M.;
Schellens, Jan H. M.;
Rodenhuis, Sjoerd;
Beijnen, Jos H.

Publication type:

Article

Population pharmacokinetics of thioTEPA and its active metabolite TEPA in patients undergoing high-dose chemotherapy.

Published in:

British Journal of Clinical Pharmacology, 2001, v. 51, n. 1, p. 61, doi. 10.1046/j.1365-2125.2001.01301.x

By:

Huitema, Alwin D. R.;
Mathôt, Ron A. A.;
Tibben, Matthijs M.;
Schellens,, Jan H. M.;
Rodenhuis, Sjoerd;
Beijnen, Jos H.

Publication type:

Article

P‐glycoprotein (MDR1/ABCB1) controls brain accumulation and intestinal disposition of the novel TGF‐β signaling pathway inhibitor galunisertib.

Published in:

International Journal of Cancer, 2020, v. 146, n. 6, p. 1631, doi. 10.1002/ijc.32568

By:

Li, Wenlong;
Tibben, Matthijs;
Wang, Yaogeng;
Lebre, Maria C.;
Rosing, Hilde;
Beijnen, Jos H.;
Schinkel, Alfred H.

Publication type:

Article

Development and validation of a bioanalytical method for the quantification of the CDK4/6 inhibitors abemaciclib, palbociclib, and ribociclib in human and mouse matrices using liquid chromatography-tandem mass spectrometry.

Published in:

Analytical & Bioanalytical Chemistry, 2019, v. 411, n. 20, p. 5331, doi. 10.1007/s00216-019-01932-w

By:

Martínez-Chávez, Alejandra;
Rosing, Hilde;
Hillebrand, Michel;
Tibben, Matthijs;
Schinkel, Alfred H.;
Beijnen, Jos H.

Publication type:

Article

Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy.

Published in:

Investigational New Drugs, 2015, v. 33, n. 1, p. 201, doi. 10.1007/s10637-014-0179-1

By:

Leijen, Suzanne;
Burgers, Sjaak;
Baas, Paul;
Pluim, Dick;
Tibben, Matthijs;
Werkhoven, Erik;
Alessio, Enzo;
Sava, Gianni;
Beijnen, Jos;
Schellens, Jan

Publication type:

Article

Overestimation of the effect of (fos)aprepitant on intravenous dexamethasone pharmacokinetics requires adaptation of the guidelines for children with chemotherapy-induced nausea and vomiting.

Published in:

Supportive Care in Cancer, 2022, v. 30, n. 12, p. 9991, doi. 10.1007/s00520-022-07423-6

By:

Nijstad, A. Laura;
de Vos-Kerkhof, Evelien;
Enters-Weijnen, Catherine F.;
van de Wetering, Marianne D.;
Tissing, Wim J. E.;
Tibben, Matthijs M.;
Rosing, Hilde;
Lalmohamed, Arief;
Huitema, Alwin D. R.;
Zwaan, C. Michel

Publication type:

Article

The application of inductively coupled plasma mass spectrometry in clinical pharmacological oncology research.

Published in:

Mass Spectrometry Reviews, 2008, v. 27, n. 2, p. 67, doi. 10.1002/mas.20159

By:

Brouwers, Elke E.M.;
Tibben, Matthijs;
Rosing, H.;
Schellens, Jan H.M.;
Beijnen, Jos H.

Publication type:

Article

Reduction of cyclophosphamide bioactivation by thioTEPA: critical sequence-dependency in high-dose chemotherapy regimens.

Published in:

Cancer Chemotherapy & Pharmacology, 2000, v. 46, n. 2, p. 119, doi. 10.1007/s002800000132

By:

Huitema, Alwin D. R.;
Kerbusch, Thomas;
Tibben, Matthijs M.;
Rodenhuis, Sjoerd;
Beijnen, Jos H.

Publication type:

Article